Emerging Technologies Powering Rare and Neglected Disease Diagnosis and Therapy Development

80.4K

views

21

articles

Editorial

05 April 2022

Editorial: Emerging Technologies Powering Rare and Neglected Disease Diagnosis and Theraphy Development

Zhichao Liu

,

Qais Hatim

,

Shraddha Thakkar

,

Ruth Roberts

and

Tieliu Shi

1,647 views

4 citations

Editors

5

Zhichao Liu

Boehringer Ingelheim (United States)

Ruth Roberts

ApconiX

Shraddha Thakkar

United States Food and Drug Administration

Qais Y. Hatim

United States Food and Drug Administration

Tieliu Shi

Impact

Fetching...

About

There are more than 7,000 identified rare and neglected diseases, yet only about 600 treatments are available. Obstacles such as incomplete knowledge of disease natural history hinder the etiology and pathogenesis understanding of rare and neglected diseases. Emerging technologies including Artificial Intelligence (AI), advanced bioengineering, and next-generation sequencing (NGS) provide unprecedented opportunity to accelerate rare and neglected disease diagnosis and treatment development.

We welcome investigators to contribute with Original Research articles, as well as Review or Opinion articles that seek to address how emerging technology can advance rare and neglected disease diagnosis and treatment development. A particular interest will be given to papers exploring or discussing the application of the integration of AI and pharmacogenomics to advance rare and neglected disease therapy development.

Potential subtopics include, but are not limited to the following:
(1) Drug repositioning for treatment development of rare and neglected diseases.
(2) AI-based mythologies and approaches for facilitating information retrieval on rare and neglected diseases.
(3) Integrative approaches of diverse biological information for rare and neglected diseases diagnosis and treatment development.
(4) Integration of pharmacogenetics/omics for enhancing drug repositioning of rare and neglected diseases.
(5) Precision medicine for treatment development of COVID-19 for different vulnerable populations and patients with different preexisting conditions.
(6) Data standardization of rare and neglected disease terminology and ontology development.
(7) Advanced techniques for efficient utilization of high-performance computing clusters and cloud systems for powering AI for rare and neglected diseases.

Topic Editor Professor Ruth Roberts is the Chair and Director of Drug Discovery at The University of Birmingham and Co-founder ApconiX Ltd. All other Topic Editors declare no competing interests with regards to the Research Topic subject.

Download ebook

PDF

EPUB

Share

Editors

Zhichao Liu

Boehringer Ingelheim (United States)

Ruth Roberts

ApconiX

Shraddha Thakkar

United States Food and Drug Administration

Qais Y. Hatim

United States Food and Drug Administration

Tieliu Shi

Impact

80,428 Total views

58,045 Article views

20,845 Article downloads

1,538 Topic views

Published In

Frontiers in Pharmacology

Pharmacogenetics and Pharmacogenomics, Translational Pharmacology

Frontiers in Genetics

Pharmacogenetics and Pharmacogenomics, Genetics of Common and Rare Diseases

Frontiers in Pediatrics

Genetics of Common and Rare Diseases

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic